The photonics-as-AI-bottleneck claim has faded, leaving Lumentum facing more pain before the theme recovers. A large December options node sits at $600; the stock bot targets downside at $650 and $595, with $581 a possible liquidity sweep where smart money would buy instead of rushing in at $650 or $630. Most photonics companies will likely never come back. x.com 

Marvell risks paying a peak-scarcity price for Lumentum if optical supply catches up by 2028-30. The proposed ~$99B deal values Lumentum at roughly 20x guided annualized revenue and 58x estimated after-tax operating income, while Lumentum, Coherent and Chinese suppliers are adding laser capacity. The DSP-and-laser combination has strategic logic, but durable scarcity economics and Nvidia's response remain uncertain. x.com 

Lumentum's AI-optics case gains longer supply visibility: CEO Michael Hurlston says capacity is effectively sold out through early 2029 and expects roughly 70% of demand for some products to go unmet through 2027; others could face roughly 30% unmet demand through 2028. Scarcity could support pricing, but earnings growth depends on capacity expansion and yield improvements translating into shipments, revenue and margins. x.com 

Owning Lumentum's laser fab could secure Marvell's FY28 supply and hedge its DSP franchise as optical links shift to CPO. The rumored deal's strategy makes sense, but short-term pain is likely: at a 30% premium, roughly $17.5B in new debt and the rest in stock, rough math puts EPS dilution near 15%. It turns accretive only if Lumentum outgrows Marvell at today's guided rates for five or six more quarters, which looks achievable while the laser shortage lasts. x.com  x.com  x.com 

Optical component stocks such as Lumentum, Coherent, Applied Optoelectronics and AXT look early in an unwind, as a wave of new photonics paid newsletters signals a crowded narrative. Price pays; narratives do not. x.com 

Lumentum's 109% year-on-year growth and sold-out capacity through 2029 make selling its AI optics exposure questionable. Bloomberg reported Marvell is in advanced talks to buy it; the appeal depends on the price, especially when holders of an $80 billion Lumentum would become holders of a $320 billion-plus Marvell growing 37%. x.com 

Lumentum is a great business, but at $954 its risk/reward is not attractive. Applying 30x to fiscal 2028 non-GAAP EPS of $40 gives a 2027 price target of $1,200, about 26% upside, or roughly 15% after adjusting for execution, financial, technology and supply risks. Reaching it needs on-time manufacturing ramps, sustained pricing power and cash flow without excessive dilution. Lost pricing power plus slipping OCS or laser ramps would break the thesis; a significant dip would offer a better entry. … Show more

Lumentum requires paying up heavily for a company that is not yet making money. Revenue grew 109% year over year, but it trades at about 25 times annualized sales, and it is growing less than memory makers at ten times their valuation. @ZeekTyt cites Lumentum's CEO expecting to supply only about 30% of requested laser demand as CPO and NPO ramp in 2027, with balance around 2029-30. x.com  x.com 

Photonics still has room for a memory-type run because new laser capacity takes years to reach customers. Despite the sector's big gains, the upside still looks enormous: Lumentum's CEO says it is effectively sold out through early 2029, versus 2028 a few months ago. It cannot meet about 70% of demand for some products through next year and about 30% for others through 2028; relief is not expected before 2029-30. x.com 

Lumentum, AXT and Coherent face potential delays to CPO and 800V, and their charts started flopping as if the stocks knew ahead of time. Per @BULLOFBRITAIN, citing a SemiAnalysis report, CPO and 800V could be pushed back to 2028–29 while NPO potentially accelerates, with caution urged on names including Lumentum. x.com